eplontersen是一种配体偶联反义(LICA)药物，可减少转甲状腺素蛋白（TTR）的产生。 ATTR淀粉样变性（图片来源：clevelandclinic.org ...

In a review published in Therapeutics and Clinical Risk Management, researchers outlined the current understanding of the transthyretin amyloidosis (ATTR) disease process, diagnostic and surveillance ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced the submission of a Type II Variation to the ...

“Estimates show approximately 100,000 people are affected by ATTR amyloidosis across Europe, most with cardiomyopathy, so this approval marks a critical step toward addressing this underserved patient ...

Intellia Therapeutics, Inc. announced key operational and financial updates for the first quarter of 2025, highlighting significant progress in its clinical trials. The company is on track to complete ...

Novo Nordisk has struck a $1.2 billion deal to buy Prothena’s ATTR amyloidosis program, which was stalled by the pandemic last year. The deal will see Novo pay $100 million in upfront and near-term ...